Your browser doesn't support javascript.
loading
A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia.
Avis, H J; Vissers, M N; Stein, E A; Wijburg, F A; Trip, M D; Kastelein, J J P; Hutten, B A.
Afiliación
  • Avis HJ; Academic Medical Centre, Department of Vascular Medicine, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Arterioscler Thromb Vasc Biol ; 27(8): 1803-10, 2007 Aug.
Article en En | MEDLINE | ID: mdl-17569881
ABSTRACT

OBJECTIVE:

Functional and morphological changes of the arterial wall already present in young children with heterozygous familial hypercholesterolemia (HeFH) suggest that treatment should be initiated early in life to prevent premature atherosclerotic cardiovascular disease. The purpose of this study was to assess the efficacy and particularly safety of statin therapy in children with HeFH. METHODS AND

RESULTS:

We performed a meta-analysis of randomized, double-blind, placebo-controlled trials evaluating statin therapy in children aged 8 to 18 years with HeFH. Six studies (n=798 children) with 12 to 104 weeks of treatment were included. Total cholesterol, LDL cholesterol, and apolipoprotein B were significantly reduced, whereas HDL cholesterol and apolipoprotein A1 were significantly increased by statin therapy. No statistically significant differences were found between statin- and placebo-treated children with respect to the occurrence of adverse events (RR 0.99; 95% CI 0.79 to 1.25), sexual development (RR of advancing > or = 1 stage in Tanner classification 0.96; 95% CI 0.79 to 1.17), muscle toxicity (RR of CK > or = 10 times the upper limit of normal [ULN] 1.38; 95% CI 0.18 to 10.82), or liver toxicity (RR of > or = 3 times the ULN for ASAT 0.98; 95% CI 0.23 to 4.26 and for ALAT 2.03; 95% CI 0.24 to 16.95). We found a minimal difference in growth in favor of the statin group (0.33 cm; 95% CI 0.03 cm to 0.63 cm).

CONCLUSION:

In addition to the fact that statin treatment is efficacious, our results support the notion that statin treatment in children with HeFH is safe. Thus, even though further studies are required to assess lifelong safety, statin treatment should be considered for all children aged 8 to 18 with HeFH.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Hiperlipoproteinemia Tipo II Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Systematic_reviews Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Arterioscler Thromb Vasc Biol Asunto de la revista: ANGIOLOGIA Año: 2007 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Hiperlipoproteinemia Tipo II Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Systematic_reviews Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Arterioscler Thromb Vasc Biol Asunto de la revista: ANGIOLOGIA Año: 2007 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA